Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group's Subsidiary Paths Innovations Limited

Regulatory News:


Aptorum Group Limited , today announced that its wholly owned subsidiary Aptorum Therapeutics Limited has entered into a non-binding Letter of Intent and Term Sheet to merge ... | May 1, 2023

Related Keywords

Boston ,Massachusetts ,United States ,San Diego ,California ,Singapore , ,Singapore Agency For Science ,Aptorum Therapeutics Limited ,Aptorum Group Or Company ,Aptorum Group Form ,Paths Innovation ,Pathsdx Group ,Technology Corporation ,Aptorum Group Limited Nasdaq ,Dx Program ,Daptorum Group ,Regulatory News ,Group Limited ,Euronext Paris ,Term Sheet ,Paths Innovation Limited ,Universal Sequencing Technology Corporation ,Innovation Limited ,Paths Diagnostics ,Sequencing Technology Corporation ,Next Generation Sequencing ,Aptorum Group Limited ,Securities Litigation Reform Act ,French Autorit ,Des March ,Regulations Delegated ,Aptorum Group Limited Stock Exchange ,News ,Information ,Press Release ,Egulatory ,Group ,Imited ,Oday ,Nnounced ,Hat ,Its ,Holly ,Wned ,Ubsidiary ,Aptorum ,Herapeutics ,Gas ,Ntered ,Into ,Setter ,F ,Intent ,End ,Term ,Sheet ,O ,Erge Apm Kyg6096m1226 ,